<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="is appreciated. During May 19–September 28, 2019,* low levels of" exact="influenza" post="activity were reported in the United States, with cocirculation"/>
 <result pre="activity were reported in the United States, with cocirculation of" exact="influenza" post="A and influenza B viruses. In the Southern Hemisphere"/>
 <result pre="in the United States, with cocirculation of influenza A and" exact="influenza" post="B viruses. In the Southern Hemisphere seasonal influenza viruses"/>
 <result pre="A and influenza B viruses. In the Southern Hemisphere seasonal" exact="influenza" post="viruses circulated widely, with influenza A(H3) predominating in many"/>
 <result pre="In the Southern Hemisphere seasonal influenza viruses circulated widely, with" exact="influenza" post="A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and"/>
 <result pre="circulated widely, with influenza A(H3) predominating in many regions; however," exact="influenza" post="A(H1N1)pdm09 and influenza B viruses were predominant in some"/>
 <result pre="influenza A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and" exact="influenza" post="B viruses were predominant in some countries. In late"/>
 <result pre="Health Organization (WHO) recommended components for the 2020 Southern Hemisphere" exact="influenza" post="vaccine and included an update to the A(H3N2) and"/>
 <result pre="included an update to the A(H3N2) and B/Victoria-lineage components. Annual" exact="influenza" post="vaccination is the best means for preventing influenza illness"/>
 <result pre="components. Annual influenza vaccination is the best means for preventing" exact="influenza" post="illness and its complications, and vaccination before influenza activity"/>
 <result pre="for preventing influenza illness and its complications, and vaccination before" exact="influenza" post="activity increases is optimal. Health care providers should recommend"/>
 <result pre="laboratories in the United States tested 7,637 respiratory specimens for" exact="influenza" post="viruses; 1,737 (22.7%) were positive (Figure 1), including 1,213"/>
 <result pre="1,737 (22.7%) were positive (Figure 1), including 1,213 (69.8%) for" exact="influenza" post="A viruses and 524 (30.2%) for influenza B viruses."/>
 <result pre="1,213 (69.8%) for influenza A viruses and 524 (30.2%) for" exact="influenza" post="B viruses. Among the 1,154 seasonal influenza A-positive specimens"/>
 <result pre="524 (30.2%) for influenza B viruses. Among the 1,154 seasonal" exact="influenza" post="A-positive specimens that were subtyped, 324 (28.1%) were influenza"/>
 <result pre="seasonal influenza A-positive specimens that were subtyped, 324 (28.1%) were" exact="influenza" post="A(H1N1)pdm09, and 830 (71.9%) were influenza A(H3N2). Among the"/>
 <result pre="subtyped, 324 (28.1%) were influenza A(H1N1)pdm09, and 830 (71.9%) were" exact="influenza" post="A(H3N2). Among the 440 influenza B viruses for which"/>
 <result pre="A(H1N1)pdm09, and 830 (71.9%) were influenza A(H3N2). Among the 440" exact="influenza" post="B viruses for which lineage was determined, 413 (93.9%)"/>
 <result pre="testing positive for influenza* reported by public health laboratories, by" exact="influenza" post="virus type, subtype/lineage, and surveillance week — United States,"/>
 <result pre="below their region-specific baselines. One human infection with a novel" exact="influenza" post="A virus§ was reported, an influenza A(H1N1) variant virus."/>
 <result pre="infection with a novel influenza A virus§ was reported, an" exact="influenza" post="A(H1N1) variant virus. This virus had hemagglutinin (HA) and"/>
 <result pre="(HA) and neuraminidase gene segments derived from the seasonal human" exact="influenza" post="A(H1N1)pdm09 virus that were likely introduced into swine by"/>
 <result pre="by a recent reverse zoonosis and were closely related to" exact="influenza" post="A(H1N1) viruses now circulating in the U.S. swine population."/>
 <result pre="the U.S. swine population. The percentage of deaths attributed to" exact="pneumonia" post="and influenza from CDC’s National Center for Health Statistics"/>
 <result pre="swine population. The percentage of deaths attributed to pneumonia and" exact="influenza" post="from CDC’s National Center for Health Statistics Mortality Surveillance"/>
 <result pre="during this period were reported to CDC. Additional information on" exact="influenza" post="surveillance methods is available at https://www.cdc.gov/flu/weekly/overview.htm, and a full"/>
 <result pre="is available at https://www.cdc.gov/flu/weekly/overview.htm, and a full description of U.S." exact="influenza" post="activity over the summer months is available in the"/>
 <result pre="influenza activity over the summer months is available in the" exact="influenza" post="surveillance report, FluView (https://www.cdc.gov/flu/weekly/). The timing of influenza activity"/>
 <result pre="in the influenza surveillance report, FluView (https://www.cdc.gov/flu/weekly/). The timing of" exact="influenza" post="activity and the predominant circulating virus in the Southern"/>
 <result pre="region.¶ Influenza A(H3N2) viruses were predominant in most regions; however," exact="influenza" post="A(H1N1)pdm09 and influenza B/Victoria viruses predominated in several countries."/>
 <result pre="viruses were predominant in most regions; however, influenza A(H1N1)pdm09 and" exact="influenza" post="B/Victoria viruses predominated in several countries. Additional information on"/>
 <result pre="B/Victoria viruses predominated in several countries. Additional information on global" exact="influenza" post="virus circulation is available at https://www.who.int/influenza/surveillance_monitoring/updates/en/. Genetic and Antigenic"/>
 <result pre="and Antigenic Characterization of Influenza Viruses CDC genetically characterized 867" exact="influenza" post="viruses submitted by U.S. and international laboratories during May"/>
 <result pre="and international laboratories during May 19–September 28, 2019, including 263" exact="influenza" post="A(H1N1)pdm09 viruses, 427 influenza A(H3N2) viruses, and 177 influenza"/>
 <result pre="May 19–September 28, 2019, including 263 influenza A(H1N1)pdm09 viruses, 427" exact="influenza" post="A(H3N2) viruses, and 177 influenza B viruses. All A(H1N1)pdm09"/>
 <result pre="263 influenza A(H1N1)pdm09 viruses, 427 influenza A(H3N2) viruses, and 177" exact="influenza" post="B viruses. All A(H1N1)pdm09 viruses belonged to genetic subclade"/>
 <result pre="cell-culture propagated 2019–20 Northern Hemisphere vaccine virus component. The 427" exact="influenza" post="A(H3N2) viruses analyzed belonged to either clades 3C.2a (354;"/>
 <result pre="collected during May 19–September 28, 2019 All 21 of the" exact="influenza" post="B/Yamagata lineage viruses analyzed belonged to clade Y3. All"/>
 <result pre="the HA protein belonged to subclade V1A-3Del. Among the 156" exact="influenza" post="B/Victoria lineage viruses analyzed, the HA gene belonged to"/>
 <result pre="V1A-3Del viruses. Antiviral Resistance of Influenza Viruses CDC tested 812" exact="influenza" post="virus specimens collected during May 19–September 28 from the"/>
 <result pre="and zanamivir. All but two of the viruses tested (245" exact="influenza" post="A(H1N1)pdm09 viruses [161 international and 84 U.S. viruses], 406"/>
 <result pre="influenza A(H1N1)pdm09 viruses [161 international and 84 U.S. viruses], 406" exact="influenza" post="A(H3N2) viruses [284 international and 122 U.S.], and 161"/>
 <result pre="influenza A(H3N2) viruses [284 international and 122 U.S.], and 161" exact="influenza" post="B viruses [71 international and 90 U.S.]) were susceptible"/>
 <result pre="viruses [71 international and 90 U.S.]) were susceptible to these" exact="influenza" post="antiviral medications. One (0.1%) influenza A(H1N1)pdm09 virus contained the"/>
 <result pre="U.S.]) were susceptible to these influenza antiviral medications. One (0.1%)" exact="influenza" post="A(H1N1)pdm09 virus contained the H275Y amino acid substitution in"/>
 <result pre="highly reduced inhibition by oseltamivir and peramivir, and one (0.1%)" exact="influenza" post="B virus contained the amino acid substitution I221T and"/>
 <result pre="reduced inhibition by the same two neuraminidase inhibitors. Among 824" exact="influenza" post="virus specimens (253 A(H1N1)pdm09, 406 A(H3N2) and 165 type"/>
 <result pre="of resistance to the adamantanes (amantadine and rimantadine) persisted among" exact="influenza" post="A(H1N1)pdm09 and influenza A(H3N2) viruses, which is consistent with"/>
 <result pre="the adamantanes (amantadine and rimantadine) persisted among influenza A(H1N1)pdm09 and" exact="influenza" post="A(H3N2) viruses, which is consistent with the current recommendation"/>
 <result pre="of the 2020 Southern Hemisphere Influenza Vaccine WHO recommendations for" exact="influenza" post="vaccine composition for the Southern Hemisphere 2020 season were"/>
 <result pre="Switzerland.†† The recommended components for the 2020 Southern Hemisphere egg-based" exact="influenza" post="trivalent vaccines are an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A/South"/>
 <result pre="a cell-propagated A/Iowa/60/2018-like virus. Discussion From May to September 2019," exact="influenza" post="activity remained low in the United States, as is"/>
 <result pre="A and B viruses cocirculated throughout the summer months with" exact="influenza" post="A(H3N2) viruses predominating overall and influenza B/Victoria, subclade V1A-3Del,"/>
 <result pre="the summer months with influenza A(H3N2) viruses predominating overall and" exact="influenza" post="B/Victoria, subclade V1A-3Del, viruses the most common influenza B"/>
 <result pre="overall and influenza B/Victoria, subclade V1A-3Del, viruses the most common" exact="influenza" post="B virus reported by public health laboratories. Influenza A"/>
 <result pre="however, regardless of what is circulating, the best protection against" exact="influenza" post="is an influenza vaccination. Influenza vaccination has been shown"/>
 <result pre="what is circulating, the best protection against influenza is an" exact="influenza" post="vaccination. Influenza vaccination has been shown to reduce the"/>
 <result pre="Influenza vaccination has been shown to reduce the risk for" exact="influenza" post="illness associated with outpatient health care visits and hospitalizations"/>
 <result pre="care visits and hospitalizations and reduces the risk for serious" exact="influenza" post="outcomes that can result in hospitalization or death. CDC"/>
 <result pre="September, WHO issued its recommendations for the 2020 Southern Hemisphere" exact="influenza" post="vaccine. Compared with the composition of the 2019–20 Northern"/>
 <result pre="vaccine. Compared with the composition of the 2019–20 Northern Hemisphere" exact="influenza" post="vaccine formulation, these recommendations reflect changes to the A(H3N2)"/>
 <result pre="example, activity in Australia during recent seasons has not reflected" exact="influenza" post="virus activity in the subsequent U.S. season. Changes to"/>
 <result pre="might not be a good predictor of the upcoming U.S." exact="influenza" post="season. Although Australia experienced an early start to its"/>
 <result pre="Australia experienced an early start to its 2019 season with" exact="influenza" post="A(H1N1)pdm09 viruses circulating initially and A(H3N2) virus eventually predominating"/>
 <result pre="A(H1N1)pdm09 viruses circulating initially and A(H3N2) virus eventually predominating (2)," exact="influenza" post="is unpredictable, and circumstances can change very quickly. Analysis"/>
 <result pre="of the Northern Hemisphere vaccine viruses used in production of" exact="influenza" post="vaccines for the upcoming U.S. season. Except for one"/>
 <result pre="influenza vaccines for the upcoming U.S. season. Except for one" exact="influenza" post="A(H1N1)pdm09 virus and one influenza B virus, all influenza"/>
 <result pre="U.S. season. Except for one influenza A(H1N1)pdm09 virus and one" exact="influenza" post="B virus, all influenza viruses tested remained susceptible to"/>
 <result pre="one influenza A(H1N1)pdm09 virus and one influenza B virus, all" exact="influenza" post="viruses tested remained susceptible to oseltamivir, peramivir, and zanamivir,"/>
 <result pre="baloxavir. Influenza antiviral medications are a valuable adjunct to annual" exact="influenza" post="vaccination, and early treatment with influenza antiviral medication, especially"/>
 <result pre="valuable adjunct to annual influenza vaccination, and early treatment with" exact="influenza" post="antiviral medication, especially within 48 hours of symptom onset,"/>
 <result pre="symptom onset, is recommended for patients with confirmed or suspected" exact="influenza" post="who 1) have severe, complicated, or progressive illness; 2)"/>
 <result pre="symptom improvement (4–7) and to reduce secondary complications associated with" exact="influenza" post="(8,9). Health care providers should not delay treatment until"/>
 <result pre="effective when given early in the illness. Additional information regarding" exact="influenza" post="viruses, influenza surveillance, influenza vaccines, influenza antiviral medications, and"/>
 <result pre="given early in the illness. Additional information regarding influenza viruses," exact="influenza" post="surveillance, influenza vaccines, influenza antiviral medications, and novel influenza"/>
 <result pre="in the illness. Additional information regarding influenza viruses, influenza surveillance," exact="influenza" post="vaccines, influenza antiviral medications, and novel influenza A virus"/>
 <result pre="illness. Additional information regarding influenza viruses, influenza surveillance, influenza vaccines," exact="influenza" post="antiviral medications, and novel influenza A virus infections in"/>
 <result pre="viruses, influenza surveillance, influenza vaccines, influenza antiviral medications, and novel" exact="influenza" post="A virus infections in humans is available at https://www.cdc.gov/flu."/>
 <result pre="https://www.cdc.gov/flu. Summary What is already known about this topic? Although" exact="influenza" post="activity is typically low in the United States during"/>
 <result pre="summer months, CDC collects, compiles, and analyzes data to monitor" exact="influenza" post="activity throughout the year. What is added by this"/>
 <result pre="What is added by this report? In the United States," exact="influenza" post="activity remained low with cocirculation of influenza A and"/>
 <result pre="the United States, influenza activity remained low with cocirculation of" exact="influenza" post="A and influenza B viruses. Influenza viruses circulated widely"/>
 <result pre="influenza activity remained low with cocirculation of influenza A and" exact="influenza" post="B viruses. Influenza viruses circulated widely in the Southern"/>
 <result pre="Southern Hemisphere, with A(H3) viruses predominating in most regions, although" exact="influenza" post="A(H1N1)pdm09 and influenza B/Victoria viruses predominated in several countries."/>
 <result pre="A(H3) viruses predominating in most regions, although influenza A(H1N1)pdm09 and" exact="influenza" post="B/Victoria viruses predominated in several countries. What are the"/>
 <result pre="are the implications for public health practice? Receiving a seasonal" exact="influenza" post="vaccine each year remains the best way to protect"/>
 <result pre="each year remains the best way to protect against seasonal" exact="influenza" post="and its potentially severe consequences. Acknowledgments State, county, city,"/>
 <result pre="CDC. *Data reported as of October 4, 2019. †The CDC" exact="influenza" post="surveillance system collects five categories of information from eight"/>
 <result pre="the National Respiratory and Enteric Virus Surveillance System, and novel" exact="influenza" post="A virus case reporting); 2) outpatient illness surveillance (U.S."/>
 <result pre="additional states); and 5) summary of the geographic spread of" exact="influenza" post="(state and territorial epidemiologist reports). https://www.cdc.gov/flu/weekly/fluactivitysurv.htm. §Influenza viruses that"/>
 <result pre="https://www.cdc.gov/flu/weekly/fluactivitysurv.htm. §Influenza viruses that circulate in swine are called swine" exact="influenza" post="viruses when isolated from swine but are called variant"/>
 <result pre="influenza viruses when isolated from swine but are called variant" exact="influenza" post="viruses when isolated from humans. Seasonal influenza viruses that"/>
 <result pre="are called variant influenza viruses when isolated from humans. Seasonal" exact="influenza" post="viruses that circulate worldwide in the human population have"/>
 <result pre="the human population have important antigenic and genetic differences form" exact="influenza" post="viruses circulating in swine. https://www.cdc.gov/flu/swineflu/variant/preventspreadfactsheet.htm. ¶In temperate climates, the"/>
 <result pre="swine. https://www.cdc.gov/flu/swineflu/variant/preventspreadfactsheet.htm. ¶In temperate climates, the onset and peak of" exact="influenza" post="activity might vary substantially from one influenza season to"/>
 <result pre="and peak of influenza activity might vary substantially from one" exact="influenza" post="season to the next, but generally begins to increase"/>
 <result pre="fall. In the Northern Hemisphere’s temperate regions, annual epidemics of" exact="influenza" post="typically occur during October–February, but the peak of influenza"/>
 <result pre="of influenza typically occur during October–February, but the peak of" exact="influenza" post="activity can occur as late as April or May."/>
 <result pre="April or May. In temperate regions of the Southern Hemisphere," exact="influenza" post="activity typically peaks during May–August. Although temperate regions of"/>
 <result pre="temperate regions of the world experience a seasonal peak in" exact="influenza" post="activity, influenza viruses can be isolated year-round. The timing"/>
 <result pre="of the world experience a seasonal peak in influenza activity," exact="influenza" post="viruses can be isolated year-round. The timing of seasonal"/>
 <result pre="can be isolated year-round. The timing of seasonal peaks in" exact="influenza" post="activity in tropical and subtropical countries varies by region."/>
 <result pre="the same year have been observed in some areas, and" exact="influenza" post="infection can occur year-round. **A virus is considered similar"/>
 <result pre="≥65 years; 3) persons with chronic pulmonary conditions (including asthma)," exact="cardiovascular disease" post="(except hypertension alone), renal, hepatic, hematologic (including sickle cell)"/>
 <result pre="the brain, spinal cord, peripheral nerves, and muscles, such as" exact="cerebral palsy," post="epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate"/>
 <result pre="spinal cord, peripheral nerves, and muscles, such as cerebral palsy," exact="epilepsy" post="[seizure disorders], stroke, intellectual disability [mental retardation], moderate to"/>
 <result pre="stroke, intellectual disability [mental retardation], moderate to severe developmental delay," exact="muscular dystrophy," post="or spinal cord injury); 4) persons with immunosuppression, including"/>
 <result pre="aspirin therapy; 7) American Indians/Alaska Natives; 8) persons with extreme" exact="obesity" post="(i.e., body mass index ≥40); and 9) residents of"/>
 <result pre="U.S. patent no. 10,272,149 for a live, synthetic, modified bat" exact="influenza" post="virus strain useful for vaccination against a target influenza"/>
 <result pre="bat influenza virus strain useful for vaccination against a target" exact="influenza" post="strain, outside the current work. No other potential conflicts"/>
 <result pre="AlyanakE, BroderKR, WalterEB, FryAM, JerniganDB. Prevention and control of seasonal" exact="influenza" post="with vaccines: recommendations of the Advisory Committee on Immunization"/>
 <result pre="recommendations of the Advisory Committee on Immunization Practices—United States, 2019–20" exact="influenza" post="season.MMWR Recomm Rep2019;68(No. RR-3). 10.15585/mmwr.rr6803a131441906 2. BarrIG, DengYM, GrauML,"/>
 <result pre="Rep2019;68(No. RR-3). 10.15585/mmwr.rr6803a131441906 2. BarrIG, DengYM, GrauML, et al.Intense interseasonal" exact="influenza" post="outbreaks, Australia, 2018/19.Euro Surveill2019;24:1900421. 10.2807/1560-7917.ES.2019.24.33.190042131431210 3. FioreAE, FryA, ShayD,"/>
 <result pre="4. HedrickJA, BarzilaiA, BehreU, et al.Zanamivir for treatment of symptomatic" exact="influenza" post="A and B infection in children five to twelve"/>
 <result pre="10.1097/00006454-200005000-0000510819336 5. HeinonenS, SilvennoinenH, LehtinenP, et al.Early oseltamivir treatment of" exact="influenza" post="in children 1–3 years of age: a randomized controlled"/>
</results>
